Bio-Rad Laboratories Inc Class A
BIO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$265.00 | Ksdq | Zptmjfkk |
Narrow-Moat Bio-Rad Reports Solid Q3 Buoyed by Royalties, COVID-19, and Currency Effects
Bio-Rad saw a strong quarter across the board in the third quarter, with currency neutral sales growth of 13.8% and EPS growth of 24%, excluding income and taxes from Sartorius. We are maintaining our $455 fair value estimate and our narrow moat and high uncertainty ratings. We continue to believe the market is overestimating Bio-Rad’s postpandemic growth prospects.